← Search & browse all drugs

beclometasone

R03BA01

Forms & Strengths

Metered‑dose inhaler (MDI) 50 µg per actuation
Metered‑dose inhaler (MDI) 100 µg per actuation
Dry‑powder inhaler (DPI) 100 µg per inhalation
Nasal spray 50 µg per spray
Nebuliser suspension 0.5 mg/2 mL

Adult Dosing

Inhaled asthma maintenance: 200‑400 µg once daily or divided BID (2‑4 puffs of 50 µg)
Step‑down: taper to lowest effective dose after control
Exacerbation add‑on: increase to 400‑800 µg/day for ≤2 weeks
Nasal allergic rhinitis: 1‑2 sprays per nostril once daily (50‑100 µg total)

Pediatric Dosing

Children 5‑12 yr: 100‑200 µg/day (1‑2 puffs of 50 µg) for asthma maintenance
Children <5 yr: 50‑100 µg/day (1 puff of 50 µg) if device approved
Nasal spray (≥2 yr): 1 spray per nostril once daily (50 µg total)

Indications

Maintenance treatment of persistent asthma in adults and children
Prevention of exercise‑induced bronchospasm as adjunct therapy
Allergic rhinitis (intranasal formulation)

Mechanism of Action

Synthetic glucocorticoid agonist at intracellular glucocorticoid receptors
Reduces airway inflammation by inhibiting cytokine, chemokine, and eosinophil migration
Decreases mucus production and airway hyper‑responsiveness

Contraindications

Hypersensitivity to beclometasone or any excipient
Primary viral respiratory infections (including influenza)
Untreated pulmonary tuberculosis

Adverse Reactions

Oral candidiasis (thrush)
Dysphonia/hoarseness
Cough or throat irritation
Systemic effects at high doses: adrenal suppression, reduced bone mineral density, growth retardation in children
Nasal irritation or epistaxis with intranasal use

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) ↑ systemic exposure
Concurrent systemic glucocorticoids ↑ risk of HPA‑axis suppression
Concurrent high‑dose inhaled steroids ↑ risk of systemic side‑effects
Antifungals and macrolide antibiotics may modestly increase plasma levels

Curated Content: Needs Vetting Before Put to Clinical Use